
BMS buys cancer start-up Flexus for up to $1.25bn
Executive Summary
Bristol-Myers Squibb Co. paid $800mm up front for Flexus Biosciences Inc., a private cancer start-up that's also entitled to $450mm in development earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com